SCHEMBL19424902

SCHEMBL19424902

Cc1cc(S(=O)(=O)NC(=O)c2ccc(N3CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC3)cc2)ccc1NC(C)(C)CSc1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 11/20 0.63
BCL2 P10415 13/20 0.62
BAK1 Q16611 3/20 0.61
BAD Q92934 2/20 0.61
MDM4 O15151 1/20 0.61
BCL2L11 O43521 1/20 0.61
TP53 P04637 1/20 0.61
BID P55957 1/20 0.61
BAX Q07812 1/20 0.61
MCL1 Q07820 1/20 0.61
ASPH Q12797 1/20 0.61
BECN1 Q14457 1/20 0.61
BCL2L2 Q92843 1/20 0.61
BBC3 Q9BXH1 1/20 0.61
HDAC3 O15379 5/20 0.58
HDAC4 P56524 5/20 0.58
HDAC1 Q13547 5/20 0.58
HDAC7 Q8WUI4 5/20 0.58
HDAC2 Q92769 5/20 0.58
HDAC10 Q969S8 5/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2020634 0.93 BCL2L1 (0.63) BCL2L1BCL2BAK1BADMDM4
SCHEMBL2022210 0.91 BCL2L1 (0.74) BCL2L1BCL2BAK1BADMDM4
SCHEMBL19425240 0.89 BCL2 (0.60) BCL2L1BCL2BAK1BADMDM4
SCHEMBL19424249 0.88 BCL2L1 (0.60) BCL2L1BCL2BAK1BADMDM4
SCHEMBL19424225 0.88 BCL2L1 (0.65) BCL2L1BCL2BAK1BADMDM4
SCHEMBL19424358 0.87 BCL2L1 (0.59) BCL2L1BCL2
SCHEMBL19424230 0.87 BCL2L1 (0.70) BCL2L1BCL2BAK1BADMDM4
SCHEMBL1540842 0.86 BCL2L1 (0.73) BCL2L1BCL2BAK1BADMDM4
SCHEMBL19424318 0.86 BCL2L1 (0.76) BCL2L1BCL2BAK1BADMDM4
SCHEMBL19424901 0.86 BCL2L1 (0.74) BCL2L1BCL2BAK1BADMDM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170281649-A1 COMPOUNDS AND THERAPEUTIC USES UNITY BIOTECHNOLOGY, INC. 2017-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170281649-A1 COMPOUNDS AND THERAPEUTIC USES TP53, NQO1, SHMT2 BCL2L1 953/4885BCL2 520/4885BAK1 524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.